Correction to: Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis

Correction to: Arthritis Research & Therapy (2020) 22: 115

https://doi.org/10.1186/s13075-020-02199-8

Following publication of the original article [1], the authors identified errors in Fig. 1. The legends in Fig. 1c and d refer to placebo, baricitinib 4-mg and adalimumab treatment groups; the legends should refer to placebo, baricitinib 2-mg, and baricitinib 4-mg and the reference to these two studies in the figure caption are reversed. Additionally, the total number of interruptions for baricitinib 4-mg in RA-BEAM (Fig. 1b) has been corrected from 82 to 62 and the title for RA-BEAM has been corrected from 0-52 weeks to 0-24 weeks; labels have been corrected for MTX (8–14 days) in RA-BEGIN from 28 to 29 and for placebo (15–21 days) in RA-BUILD from 17 to 16.

The corrected Fig. 1 is given below.

Fig. 1

Duration of interruptions in the phase 3 studies RA-BEGIN (a), RA-BEAM (b), RA-BEACON (c), and RA-BUILD (d)^a,b. ^aInterruptions are based on daily tablet baricitinib study drug, including in non-baricitinib groups, which represent interruptions of the matching placebo for baricitinib. ^bTemporary interruption is defined as a temporary withholding of study drug that is followed by resumption of study drug during the study. MTX, methotrexate